Previous 10 | Next 10 |
2023-08-08 07:18:36 ET InspireMD press release ( NASDAQ: NSPR ): Q2 GAAP EPS of -$0.24 beats by $0.04 . Revenue of $1.65M (+7.8% Y/Y) beats by $0.08M . For further details see: InspireMD GAAP EPS of -$0.24 beats by $0.04, revenue of $1.65M beats by $0.08M
- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and secondary endpoints and, if successful, submit PMA application in H2 2024 – ...
2023-08-07 12:58:20 ET InspireMD ( NASDAQ: NSPR ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$0.30 and the consensus Revenue Estimate is $1.55M (+1.3% Y/Y). Over the last 3 months, EPS estimat...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke preve...
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company anticipates study results and Premarket Approval (PMA) submission in H2...
2023-06-12 10:36:21 ET When times are good and the market is rallying in consecutive sessions, sometimes stocks will pop on any news at all, regardless of if it’s a fundamentally altering event for the company Seeing that the S&P 500 futures are trading in positive territory as w...
TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that, in connection with the appointment of Shane Gleason as General Manager of Nor...
2023-05-16 11:24:05 ET Start Time: 08:30 End Time: 08:53 InspireMD, Inc. (NSPR) Q1 2023 Earnings Conference Call May 16, 2023, 08:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Glenn Garmont - IR, LifeSci Advisors Conference Ca...
2023-05-16 07:04:21 ET InspireMD press release ( NASDAQ: NSPR ): Q1 GAAP EPS of -$0.53 beats by $0.15 . Revenue of $1.24M (+5.1% Y/Y) beats by $0.24M . For further details see: InspireMD GAAP EPS of -$0.53 beats by $0.15, revenue of $1.24M beats by $0.24M
- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company’s CE Mark certification until mid-Marc...
News, Short Squeeze, Breakout and More Instantly...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...